

Day : Wednesday

Date: 5/30/2007

Time: 15:03:32

PALM INTRANET

**Inventor Name Search Result**

Your Search was:

Last Name = GABBAY

First Name = JEFFREY

Application#	Patent#	Status	Date Filed	Title	Inventor Name
<u>08693657</u>	5981066	250	08/09/1996	APPLICATIONS OF METALLIZED TEXTILE	GABBAY, JEFFREY
<u>08917608</u>	Not Issued	161	08/26/1997	THERMOCHEMICALLY BENIGN TEXTILE	GABBAY, JEFFREY
<u>09327400</u>	6124221	150	06/07/1999	ARTICLE OF CLOTHING HAVING ANTIBACTERIAL, ANTIFUNGAL, AND ANTIYEAST PROPERTIES	GABBAY, JEFFREY
<u>09478886</u>	Not Issued	161	01/07/2000	THERMOCHEMICALLY BENIGN TEXILE	GABBAY, JEFFREY
<u>09557669</u>	6482424	150	04/25/2000	METHODS AND FABRICS FOR COMBATING NOSOCOMIAL INFECTIONS	GABBAY, JEFFREY
<u>10133691</u>	Not Issued	161	04/24/2002	Method and device for inactivating HIV	GABBAY, JEFFREY
<u>10240993</u>	7169402	150	12/16/2002	ANTIMICROBIAL AND ANTIVIRAL POLYMERIC MATERIALS	GABBAY, JEFFREY
<u>10339886</u>	Not Issued	41	01/10/2003	Method and device for inactivating viruses	GABBAY, JEFFREY
<u>10371491</u>	Not Issued	161	02/21/2003	Disposable diaper for combating diaper rash	GABBAY, JEFFREY
<u>10405408</u>	Not Issued	41	04/01/2003	Disposable paper-based hospital and operating theater products	GABBAY, JEFFREY
<u>10752938</u>	Not Issued	61	01/06/2004	Anti-virus hydrophilic polymeric material	GABBAY, JEFFREY
<u>10756849</u>	Not Issued	71	01/13/2004	Disposable feminine hygiene products	GABBAY, JEFFREY
<u>10757786</u>	Not Issued	120	01/13/2004	Disposable diaper for combating diaper rash	GABBAY, JEFFREY
<u>10772890</u>	Not Issued	71	02/04/2004	Anti-virus hydrophilic polymeric material	GABBAY, JEFFREY

<u>10890936</u>	Not Issued	30	07/13/2004	Antimicrobial and antiviral polymeric materials and a process for preparing the same	GABBAY, JEFFREY
<u>10966138</u>	Not Issued	41	10/15/2004	Method and device for inactivating viruses	GABBAY, JEFFREY
<u>11066893</u>	Not Issued	30	02/25/2005	Device for cleaning tooth and gum surfaces	GABBAY, JEFFREY
<u>11648858</u>	Not Issued	17	12/28/2006	Antimicrobial and antiviral polymeric materials	GABBAY, JEFFREY
<u>11667095</u>	Not Issued	19	01/01/0001	Methods and materials for skin care	GABBAY, JEFFREY
<u>11667182</u>	Not Issued	19	01/01/0001	Copper containing materials for treating wounds burns and other skin conditions	GABBAY, JEFFREY
<u>11692884</u>	Not Issued	19	03/28/2007	Antimicrobial, Antifungal and Antiviral Rayon Fibers	GABBAY, JEFFREY
<u>07504557</u>	5102726	150	04/03/1990	FLEXIBLE COMPOSITE LAMINATE COMPRISING A TEXTILE SUBSTRATE, CEMENTITIOUS LAYER AND SEALING LAYER	GABBAY, JEFFREY S. S.
<u>60041324</u>	Not Issued	159	03/20/1997	ROTARY SCREEN PRINTING, STANDARD FOAM, STANDARD DIPPING STANDARD KNIFE COATING, OR A KISS-ROLL/PAD SYSTEM OF TECHNOLOGY AS A BASIS FOR BINDERLESS APPLICATION FOR PRINTING OF METALS ON TEXTILES AND OTHER MATERIALS	GABBAY, JEFFREY S. S.

Inventor Search Completed: No Records to Display.

Search Another: Inventor Last Name First Name

To go back use Back button on your browser toolbar.

Back to [PALM](#) | [ASSIGNMENT](#) | [OASIS](#) | [Home page](#)

10772890

## INVENTOR SEARCH

=&gt; d ibib abs 12 1-2

L2 ANSWER 1 OF 2 HCAPLUS COPYRIGHT 2007 ACS on STN  
 ACCESSION NUMBER: 2005:185434 HCAPLUS Full-text  
 DOCUMENT NUMBER: 142:262333  
 TITLE: Anti-virus hydrophilic polymeric material and device using it  
 INVENTOR(S): Gabbay, Jeffrey  
 PATENT ASSIGNEE(S): The Cupron Corporation, USA  
 SOURCE: U.S. Pat. Appl. Publ., 6 pp.  
 CODEN: USXXCO  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 2  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005049370	A1	20050303	US 2004-752938	20040106
US 2005048131	A1	20050303	US 2004-772890	20040204
AU 2004267961	A1	20050310	AU 2004-267961	20040720
CA 2536699	A1	20050310	CA 2004-2536699	20040720
WO 2005020689	A1	20050310	WO 2004-IL636	20040720
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1657980	A1	20060524	EP 2004-744976	20040720
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
CN 1856253	A	20061101	CN 2004-80027322	20040720
TR 200601582	T1	20070122	TR 2006-1582	20040720
JP 2007504291	T	20070301	JP 2006-524524	20040720
PRIORITY APPLN. INFO.:				
IL 2003-157625				A 20030828
US 2004-752938				A2 20040106
US 2004-772890				A 20040204
WO 2004-IL636				W 20040720

AB The invention provides a method for imparting antiviral properties to a hydrophilic polymeric material comprising preparing a hydrophilic polymeric slurry, dispersing an ionic copper powder mixture containing cuprous oxide and cupric oxide in said slurry and then extruding or molding said slurry to form a hydrophilic polymeric material, wherein water-insol. particles that release both Cu++ and Cu+ are directly and completely encapsulated within said hydrophilic polymeric material. An antiviral glove can be made from the polymeric material.

L2 ANSWER 2 OF 2 HCAPLUS COPYRIGHT 2007 ACS on STN

10/772,890

ACCESSION NUMBER: 2005:182116 HCAPLUS Full-text  
 DOCUMENT NUMBER: 142:246311  
 TITLE: Antiviral hydrophilic polymers  
 containing copper  
 INVENTOR(S): Gabbay, Jeffrey  
 PATENT ASSIGNEE(S): The Cupron Corporation, USA  
 SOURCE: U.S. Pat. Appl. Publ., 11 pp., Cont.-in-part of U.S.  
 Ser. No. 752,938.  
 CODEN: USXXCO  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 2  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005048131	A1	20050303	US 2004-772890	20040204
US 2005049370	A1	20050303	US 2004-752938	20040106
AU 2004267961	A1	20050310	AU 2004-267961	20040720
CA 2536699	A1	20050310	CA 2004-2536699	20040720
WO 2005020689	A1	20050310	WO 2004-IL636	20040720
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1657980	A1	20060524	EP 2004-744976	20040720
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
CN 1856253	A	20061101	CN 2004-80027322	20040720
TR 200601582	T1	20070122	TR 2006-1582	20040720
JP 2007504291	T	20070301	JP 2006-524524	20040720
PRIORITY APPLN. INFO.:			IL 2003-157625	A 20030828
			US 2004-752938	A2 20040106
			US 2004-772890	A 20040204
			WO 2004-IL636	W 20040720

AB The invention provides a method for imparting antiviral properties to a hydrophilic polymeric material comprising preparing a hydrophilic polymeric slurry, dispersing an ionic copper powder mixture containing cuprous oxide and cupric oxide in said slurry and then extruding or molding said slurry to form a hydrophilic polymeric material, wherein water-insol. particles that release both Cu++ and Cu+ are directly and completely encapsulated within said hydrophilic polymeric material.

## SEARCH IN REGISTRY, CAPLUS, AND USPATFULL

=&gt; d que stat l21

```

L4      37009 SEA FILE=HCAPLUS ABB=ON  ?HYDROPHILIC?(P)?POLYMER?
L5      345 SEA FILE=HCAPLUS ABB=ON  L4 AND (?VIRUS? OR ?VIRAL?)
L6      1 SEA FILE=REGISTRY ABB=ON  (NITRILES OR ACRYLICS OR POLYVINYL
      ALCOHOL OR SILASTIC RUBBER)/CN
L8      3 SEA FILE=REGISTRY ABB=ON  "COPPER OXIDE"/CN
L9      1 SEA FILE=REGISTRY ABB=ON  COPPER/CN
L10     83 SEA FILE=HCAPLUS ABB=ON  L5 AND (L6 OR ?LATEX? OR ?NITRILE? OR
      ?ACRYLIC? OR ?POLYVINYL?(W)?ALCOHOL? OR ?SILASTIC?(W)?RUBBER?)
L11     6 SEA FILE=HCAPLUS ABB=ON  L10 AND (L8 OR L9 OR (?COPPER? OR
      ?CUPRIC?) (W)?OXID? OR ?COPPER?)
L12     13 SEA FILE=HCAPLUS ABB=ON  L10 AND (?ENCAPSULAT? OR (?FIRST? OR
      ?SECOND?) (W)?LAYER)
L13     17 SEA FILE=HCAPLUS ABB=ON  L11 OR L12
L14     10 SEA FILE=HCAPLUS ABB=ON  L13 AND (PRD<20040204 OR PD<20040204)
L15     6686 SEA FILE=USPATFULL ABB=ON  L13 AND (PRD<20040204 OR PD<20040204
      )
L16     5833 SEA FILE=USPATFULL ABB=ON  L15 AND ?ENCAPSULAT?
L17     307 SEA FILE=USPATFULL ABB=ON  L16 AND (?FIRST? OR ?SECOND?) (W)?LAY
      ER?
L18     114 SEA FILE=USPATFULL ABB=ON  L17 AND ?MULTILAYER?
L19     72 SEA FILE=USPATFULL ABB=ON  L18 AND ?HYDROPHIL?(W)?POLYMER?
L20     2 SEA FILE=USPATFULL ABB=ON  L19 AND ?INACT?(3A)?(?VIRUS? OR
      ?VIRAL?)
L21     12 DUP REMOV L14 L20 (0 DUPLICATES REMOVED)

```

=&gt; d ibib abs l21 1-12

L21 ANSWER 1 OF 12 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2005:185434 HCAPLUS Full-text

DOCUMENT NUMBER: 142:262333

TITLE: Anti-virus hydrophilic  
polymeric material and device using it

INVENTOR(S): Gabbay, Jeffrey

PATENT ASSIGNEE(S): The Cupron Corporation, USA

SOURCE: U.S. Pat. Appl. Publ., 6 pp.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005049370	A1	20050303	US 2004-752938	20040106 <--
US 2005048131	A1	20050303	US 2004-772890	20040204 <--
AU 2004267961	A1	20050310	AU 2004-267961	20040720 <--
CA 2536699	A1	20050310	CA 2004-2536699	20040720 <--
WO 2005020689	A1	20050310	WO 2004-IL636	20040720 <--

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,  
CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,  
GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,  
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,  
NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,  
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW  
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,

10/772,890

AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,  
 EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,  
 SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,  
 SN, TD, TG

EP 1657980 A1 20060524 EP 2004-744976 20040720 <--  
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
 IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK

CN 1856253 A 20061101 CN 2004-80027322 20040720 <--  
 TR 200601582 T1 20070122 TR 2006-1582 20040720 <--  
 JP 2007504291 T 20070301 JP 2006-524524 20040720 <--

PRIORITY APPLN. INFO.: IL 2003-157625 A 20030828 <--  
 US 2004-752938 A2 20040106 <--  
 US 2004-772890 A 20040204  
 WO 2004-IL636 W 20040720

AB The invention provides a method for imparting antiviral properties to a hydrophilic polymeric material comprising preparing a hydrophilic polymeric slurry, dispersing an ionic copper powder mixture containing cuprous oxide and cupric oxide in said slurry and then extruding or molding said slurry to form a hydrophilic polymeric material, wherein water-insol. particles that release both Cu++ and Cu+ are directly and completely encapsulated within said hydrophilic polymeric material. An antiviral glove can be made from the polymeric material.

L21 ANSWER 2 OF 12 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2005:182116 HCAPLUS Full-text

DOCUMENT NUMBER: 142:246311

TITLE: Antiviral hydrophilic polymers containing copper

INVENTOR(S): Gabbay, Jeffrey

PATENT ASSIGNEE(S): The Cupron Corporation, USA

SOURCE: U.S. Pat. Appl. Publ., 11 pp., Cont.-in-part of U.S. Ser. No. 752,938.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005048131	A1	20050303	US 2004-772890	20040204 <--
US 2005049370	A1	20050303	US 2004-752938	20040106 <--
AU 2004267961	A1	20050310	AU 2004-267961	20040720 <--
CA 2536699	A1	20050310	CA 2004-2536699	20040720 <--
WO 2005020689	A1	20050310	WO 2004-IL636	20040720 <--

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW  
 RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

EP 1657980 A1 20060524 EP 2004-744976 20040720 <--  
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
 IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK

10/772,890

CN 1856253	A	20061101	CN 2004-80027322	20040720 <--
TR 200601582	T1	20070122	TR 2006-1582	20040720 <--
JP 2007504291	T	20070301	JP 2006-524524	20040720 <--
PRIORITY APPLN. INFO.:			IL 2003-157625	A 20030828 <--
			US 2004-752938	A2 20040106 <--
			US 2004-772890	A 20040204
			WO 2004-IL636	W 20040720

AB The invention provides a method for imparting antiviral properties to a hydrophilic polymeric material comprising preparing a hydrophilic polymeric slurry, dispersing an ionic copper powder mixture containing cuprous oxide and cupric oxide in said slurry and then extruding or molding said slurry to form a hydrophilic polymeric material, wherein water-insol. particles that release both Cu++ and Cu+ are directly and completely encapsulated within said hydrophilic polymeric material.

L21 ANSWER 3 OF 12 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2004:824796 HCAPLUS Full-text

DOCUMENT NUMBER: 141:320084

TITLE: Polymer gels for encapsulation of biological materials

INVENTOR(S): Hubbell, Jeffrey A.; Pathak, Chandrashekhar P.; Sawhney, Amarpreet S.; Desai, Neil P.; Hossainy, Syed F. A.

PATENT ASSIGNEE(S): USA

SOURCE: U.S. Pat. Appl. Publ., 34 pp., Cont.-in-part of U.S. Ser. No. 811,901, abandoned.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 13

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004195710	A1	20041007	US 2004-761180	20040120 <--
US 5529914	A	19960625	US 1992-958870	19921007 <--
US 6258870	B1	20010710	US 1997-783387	19970113 <--
US 6231892	B1	20010515	US 1997-969910	19971113 <--
US 2002058318	A1	20020516	US 2001-811901	20010319 <--
US 6911227	B2	20050628		
US 2007100015	A1	20070503	US 2006-644606	20061222 <--

PRIORITY APPLN. INFO.:

US 1990-598880	B2	19901015 <--
US 1992-843485	B2	19920228 <--
US 1992-870540	B2	19920420 <--
US 1992-958870	A3	19921007 <--
US 1995-484160	B3	19950607 <--
US 1997-783387	A1	19970113 <--
US 2001-811901	B2	20010319 <--
US 1991-740632	A3	19910805 <--
US 1991-740703	A2	19910805 <--
US 1994-336393	A3	19941110 <--
US 2004-761180	A3	20040120 <--

AB This invention provides novel methods for the formation of biocompatible membranes around biol. materials using photopolymn. of water soluble mols. The membranes can be used as a covering to encapsulate biol. materials or biomedical devices, as a "glue" to cause more than one biol. substance to adhere together, or as carriers for biol. active species. Several methods for forming these membranes are provided. Each of these methods utilizes a polymerization system containing water-soluble macromers, species, which are

at once polymers and macromols. capable of further polymerization The macromers are polymerized using a photoinitiator (such as a dye), optionally a cocatalyst, optionally an accelerator, and radiation in the form of visible or long wavelength UV light. The reaction occurs either by suspension polymerization or by interfacial polymerization The polymer membrane can be formed directly on the surface of the biol. material, or it can be formed on material, which is already encapsulated. For example, the microcapsule interfacial polymerization method was used to form membrane around alginate-poly(L-lysine) (PLL) microcapsules containing islets. Alginate-PLL coacervated microspheres, containing one or two human pancreatic islets each, were suspended in a 1.1% CaCl<sub>2</sub> solution and aspirated free of excess solution to obtain a dense plug of microspheres. A solution of ethyl eosin (0.04% weight/volume) was prepared in a 1.1% CaCl<sub>2</sub> solution and filter-sterilized. The plug of microspheres was suspended in 10 mL of the eosin solution for 2 min to allow uptake of the dye and excess dye. was removed. A solution of PEG 18.5 tetraacrylate (2 mL; 23% weight/volume) containing 100 L of a 3.5% weight/volume solution of triethanolamine in HEPES buffered saline was added to 0.5 mL of those microspheres. The microspheres were exposed to argon ion laser light for 30 s with periodic agitation, washed with calcium solution and the process was repeated in order to further stabilize the coating. A static glucose stimulation test (SGS) confirmed the vitality and functionality of the islets.

L21 ANSWER 4 OF 12 HCAPLUS COPYRIGHT 2007 ACS on STN  
 ACCESSION NUMBER: 2004:412559 HCAPLUS Full-text  
 DOCUMENT NUMBER: 140:412329  
 TITLE: Topical compositions containing organic acids for treatment of dermal conditions  
 INVENTOR(S): Maley, Joseph C.; Gibbins, Bruce L.  
 PATENT ASSIGNEE(S): Acrymed, Inc., USA  
 SOURCE: U.S. Pat. Appl. Publ., 13 pp., Cont.-in-part of U.S. Ser. No. 207,936.  
 CODEN: USXXCO  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 2  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004096410	A1	20040520	US 2003-630627	20030729 <--
US 2004019112	A1	20040129	US 2002-207936	20020729 <--
US 6921529	B2	20050726		
WO 2004010952	A2	20040205	WO 2003-US23851	20030729 <--
WO 2004010952	A3	20041202		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003257937	A1	20040216	AU 2003-257937	20030729 <--
CN 1678277	A	20051005	CN 2003-820077	20030729 <--
PRIORITY APPLN. INFO.:			US 2002-207936	A2 20020729 <--
			US 2003-630627	A 20030729 <--



AB The present invention comprises methods and compns. for the treatment of pathol. conditions of the dermis and dermal structures of animals and humans. In particular, the present invention comprises the use of topical delivery vehicles, including hydrogels, which incorporate active agents, such as organic acids, for the treatment of dermal conditions. For example, a polyacrylamide matrix containing citric acid as the active agent was prepared. The matrix was made by dissoln. of acrylamide, bis-acrylamide, guar gum, and glycerol in the aqueous charge and then initiated and catalyzed polymerization with TEMED and sodium persulfate. A sheet of hydrophilic matrix was created by dehydration at 45° resulting in approx. 3% moisture. The sheet was then reconstituted with the addition of concentrated solns. of citric acid to form sheets so that the moisture content was approx. 50% by weight. The concentration of citric acid in the prototypes was 6%, 8%, 10%, 12%, and 16% by weight. The sheet was applied to infected nails and secured using a medical grade polyurethane adhesive thin film dressing. The cover dressing was applied so that the matrix parts were completely bordered on all sides. Matrix applied in this fashion could be worn for up to one week but typically were changed approx. every 2-3 days.

L21 ANSWER 5 OF 12 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2003:319266 HCAPLUS Full-text

DOCUMENT NUMBER: 138:343857

TITLE: Pharmaceutical formulations and systems for improved absorption and multistage release of active agents  
INVENTOR(S): Chen, Feng-Jing; Venkateshwaran, Srinivasan; Krill, Steven L.; Patel, Mahesh V.

PATENT ASSIGNEE(S): USA

SOURCE: U.S. Pat. Appl. Publ., 55 pp., Cont.-in-part of U.S. Ser. No. 898,553.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 13

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2003077297	A1	20030424	US 2002-74687	20020211 <--
US 6294192	B1	20010925	US 1999-258654	19990226 <--
US 6267985	B1	20010731	US 1999-345615	19990630 <--
US 6248363	B1	20010619	US 1999-447690	19991123 <--
US 2003064097	A1	20030403	US 2001-800593	20010306 <--
US 6569463	B2	20030527		
US 2002032171	A1	20020314	US 2001-877541	20010608 <--
US 6761903	B2	20040713		
US 2002012680	A1	20020131	US 2001-898553	20010702 <--
US 6451339	B2	20020917		
WO 2003068186	A1	20030821	WO 2003-US4195	20030211 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

10/772,890

AU 2003213020 A1 20030904 AU 2003-213020 20030211 <--  
 PRIORITY APPLN. INFO.: US 1999-258654 \* A1 19990226 <--  
 US 1999-345615 A2 19990630 <--  
 US 1999-447690 A3 19991123 <--  
 US 2001-800593 A2 20010306 <--  
 US 2001-877541 A2 20010608 <--  
 US 2001-898553 A2 20010702 <--  
 US 1999-375636 A2 19990817 <--  
 US 2000-751968 A2 20001229 <--  
 US 2002-74687 A 20020211 <--  
 WO 2003-US4195 W 20030211 <--

AB The present invention pertains to pharmaceutical formulations and systems for delivery of active agents, wherein a first fraction of an active agent is suspended in a vehicle and a second fraction of active agent is solubilized in the vehicle, with the suspended fraction representing about 5 weight % to about 80 weight % of the active agent and the second fraction representing about 20 weight % to about 95 weight % of the active agent. One or more addnl. active agents, which may be fully solubilized, partially solubilized, or suspended, may also be present. The first and second fractions of the active agent may or may not have different release profiles. Generally, a significant fraction of the solubilized drug will release rapidly, providing for rapid onset, while the suspended drug may be formulated for delayed and/or sustained release. A pharmaceutical suspension contained isotretinoin 40, soybean oil 200, Maisine 35-1 100, and Lutrol F68 100 mg.

L21 ANSWER 6 OF 12 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2002:637548 HCAPLUS Full-text

DOCUMENT NUMBER: 137:190734

TITLE: Formulations containing monoglycerides for enhancement of drug bioavailability

INVENTOR(S): Jeong, Seo-young; Kwon, Ick-chan; Chung, Hesson

PATENT ASSIGNEE(S): Korea Institute of Science and Technology, S. Korea

SOURCE: PCT Int. Appl., 42 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002064166	A1	20020822	WO 2002-KR206	20020208 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
KR 2002066778	A	20020821	KR 2001-7125	20010213 <--
AU 2002233777	A1	20020828	AU 2002-233777	20020208 <--
PRIORITY APPLN. INFO.:				
			KR 2001-7125	A 20010213 <--
			WO 2002-KR206	W 20020208 <--

AB The present invention relates to compns. and formulations to enhance bioavailability of bioactive materials and preparation method thereof. More particularly, the present invention relates to a composition comprising at least one monoglyceride, at least one emulsifier, organic solvents and aqueous

solution and a liquid and powder formulation prepared by adding bioactive material with a low bioavailability to enhance bioavailability of bioactive materials and to acquire high encapsulation efficiency of the bioactive material and high storage stability for a long period of time and preparation method thereof. For example, a liquid formulation containing tetanus toxoid was prepared. In 120 µL of ethanol, 20 mg Pluronic F-68 was dissolved (under heating if necessary). After mixing 40 µL of the 5.376 mg/mL tetanus toxoid aqueous solution and 280 mg of propylene glycol, 100 mg of monoolein and the above Pluronic F-68/ethanol solution was added to the mixture of tetanus toxoid and propylene glycol and stirred to prepare a homogeneous liquid solution. Ethanol in the formulation was evaporated completely by purging with oxygen-free nitrogen gas to prepare the viscous liquid formulation. The formulation was dispersed well in water, and the average particle size and polydispersity of the dispersion of the liquid formulation were 303.9 nm and 0.185, resp., in water and 175.2 nm and 0.377, resp., in 0.01 M sodium deoxycholate. The encapsulation efficiency of tetanus toxoid was 80-85%.

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L21 ANSWER 7 OF 12 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2001:816425 HCAPLUS Full-text

DOCUMENT NUMBER: 135:362653

TITLE: Hemostatic agent based on oxyacid salt, method and carrier for applying a blood clotting agent

INVENTOR(S): Patterson, James A.; Thompson, John A.; Keene, Talmadge Kelly; Reding, James W.

PATENT ASSIGNEE(S): Biolife, L.L.C, USA

SOURCE: PCT Int. Appl., 35 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 3

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001082896	A1	20011108	WO 2001-US13765	20010427 <--
W:			AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW	
RW:			GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG	
US 6521265	B1	20030218	US 2000-592344	20000613 <--
US 2002141964	A1	20021003	US 2001-766513	20010119 <--
EP 1276463	A1	20030122	EP 2001-930907	20010427 <--
R:			AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR	
JP 2003531850	T	20031028	JP 2001-579771	20010427 <--
BR 2001010670	A	20050524	BR 2001-10670	20010427 <--
NZ 522121	A	20051125	NZ 2001-522121	20010427 <--
ZA 2002008661	A	20031027	ZA 2002-8661	20021025 <--
IN 2002CN01760	A	20050211	IN 2002-CN1760	20021025 <--
PRIORITY APPLN. INFO.:			US 2000-200207P	P 20000428 <--
			US 2000-592344	A 20000613 <--
			US 2001-766513	A 20010119 <--
			US 2000-500902	A2 20000209 <--

AB A hemostatic agent, method and carrier for arresting the flow of blood and other protein-containing body fluids flowing from an open wound and for promoting wound healing are described. A broad aspect is directed to a substantially anhydrous admixt. of an oxyacid salt and a hydrophilic proton donor which will hydrate in the presence of blood and body fluid to produce cations to promote blood clotting. The preferred oxyacid salts are alkali and alkaline earth salts of transition metals and halogen oxyacids with oxidizing capabilities sufficient to accelerate blood clotting. Another embodiment of the invention includes the compound containing an oxysalt plus a hydrophilic polymer such as CM-cellulose, polyvinyl alc., an alginate, and all soluble gums. Still another embodiment of the invention includes the compound formed of an oxyacid salt in combination with a hydrophilic proton donor and a solid desiccant which further accelerates blood coagulation reaction rates. The cation exchange material or an admixt. of an alkali metal oxyacid salt plus acidic inorg. salt produces a scab or protective coating over the wound for protection and enhanced healing. Oxygen produced during the reaction substantially reduces the level of bacteria, virus and fungus at the wound. The resin is performance-enhanced for greater fluid uptake and more rapid coagulation.

REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L21: ANSWER 8 OF 12 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2001:780648 HCAPLUS Full-text

DOCUMENT NUMBER: 135:335147

TITLE: Polymer-based injectable sustained release pharmaceutical compositions for peptide and protein drugs

INVENTOR(S): Lee, Hee-yong; Lee, Hye-suk; Kim, Jung-soo; Kim, Sang-beom; Lee, Ji-suk; Choi, Ho-il; Chang, Seung-gu

PATENT ASSIGNEE(S): Peptron Inc., S. Korea

SOURCE: PCT Int. Appl., 37 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001078687	A1	20011025	WO 2001-KR462	20010322 <--
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
KR 2001099583	A	20011109	KR 2000-49344	20000824 <--
EP 1187602	A1	20020320	EP 2001-917893	20010322 <--
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO			
US 2003026844	A1	20030206	US 2002-18870	20020418 <--
PRIORITY APPLN. INFO.:			KR 2000-20484	A 20000418 <--
			KR 2000-49344	A 20000824 <--
			WO 2001-KR462	W 20010322 <--

AB Controlled and sustained release injectable pharmaceutical compns. for a biopharmaceutical, such as peptides and proteins are described. Processes for preparation of an injectable sustained release composition comprises (i) a step of preparing biodegradable porous microspheres having accessible ionic functional groups, (ii) a step of **encapsulating** a biopharmaceutical into the microspheres through ionic interaction by suspending or equilibrating the microspheres in a solution containing the biopharmaceutical, and (iii) a step of recovering and freeze-drying the biopharmaceutical-incorporated microspheres. For example, microspheres were prepared by water/oil/water double emulsion solvent evaporation method using a **hydrophilic 50:50 PLGA polymer (RG 502H)**, which contains free carboxy end groups. Deionized water (800 mL) was added to 1 g of PLGA polymer dissolved in 2 mL of methylene chloride and emulsified by sonication for 30 s using a probe type ultrasonic generator. This primary emulsion was dispersed into 200 mL of deionized water containing 0.5% **polyvinyl alc.** (weight/volume) in a vessel which connected to a constant temperature controller and mixed well by stirring for 15 min at 2500 rpm, 25° using a mixer. After mixing for another 15 min at 1500 rpm, 25°, temperature of continuous phase was increased to 40° to evaporate methylene chloride. After 1 h stirring at 40°, 1500 rpm, temperature was decreased to 25°. The hardened microspheres were collected by centrifugation and washed twice with 200 mL of deionized water, and then freeze-dried. The microspheres obtained were used for incorporation of protein drugs, i.e., ovalbumin, bovine serum albumin, human growth hormone, RNase A, or lysozyme through ionic interaction by simply soaking and equilibrating the microspheres into a buffer solution having an appropriate concentration of protein.

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L21 ANSWER 9 OF 12 HCAPLUS COPYRIGHT 2007 ACS on STN  
 ACCESSION NUMBER: 2001:136991 HCAPLUS Full-text  
 DOCUMENT NUMBER: 134:198075  
 TITLE: Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents  
 INVENTOR(S): Patel, Mahesh V.; Chen, Feng-Jing  
 PATENT ASSIGNEE(S): Lipocine, Inc., USA  
 SOURCE: PCT Int. Appl., 113 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 13  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001012155	A1	20010222	WO 2000-US18807	20000710 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 6309663	B1	20011030	US 1999-375636	19990817 <--
CA 2380642	A1	20010222	CA 2000-2380642	20000710 <--
EP 1210063	A1	20020605	EP 2000-947184	20000710 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
JP 2003506476	T	20030218	JP 2001-516502	20000710 <--

10/772,890

NZ 517659	A	20041224	NZ 2000-517659	20000710	<--
AU 780877	B2	20050421	AU 2000-60838	20000710	<--
US 2001024658	A1	20010927	US 2000-751968	20001229	<--
US 6458383	B2	20021001			

PRIORITY APPLN. INFO.:

```
US 1999-375636      A 19990817 <--
WO 2000-US18807     W 20000710 <--
```

AB The present invention relates to triglyceride-free pharmaceutical compns., pharmaceutical systems, and methods for enhanced absorption of hydrophilic therapeutic agents. The compns. and systems include an absorption enhancing carrier, where the carrier is formed from a combination of at least two surfactants, at least one of which is hydrophilic. A hydrophilic therapeutic agent can be incorporated into the composition, or can be co-administered with the composition as part of a pharmaceutical system. The invention also provides methods of treatment with hydrophilic therapeutic agents using these compns. and systems. For example, when a composition containing Cremophor RH40 0.30, Arlacel 186 0.20, Na taurocholate 0.18, and propylene glycol 0.32 g, resp., was used, the relative absorption of PEG 4000 as a model macromol. drug was enhanced by 991%.

REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L21 ANSWER 10 OF 12 USPATFULL on STN

ACCESSION NUMBER: 2000:124564 USPATFULL Full-text

TITLE: Anti-bacterial/anti-viral coatings, coating process and parameters thereof

INVENTOR(S): Snyder, Jr., Donald E., Brockport, NY, United States

PATENT ASSIGNEE(S): Viro-kote, Inc., Franklin, TN, United States (U.S. corporation)

	NUMBER	KIND	DATE	
	-----	----	-----	
PATENT INFORMATION:	US 6120784		20000919	<--
APPLICATION INFO.:	US 1998-172588		19981016	(9)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1997-904321, filed on 31 Jul 1997, now abandoned which is a continuation-in-part of Ser. No. US 1996-603783, filed on 20 Feb 1996, now patented, Pat. No. US 5674513			

DOCUMENT TYPE: Utility  
FILE SEGMENT: Granted  
PRIMARY EXAMINER: Clardy, S. Mark  
ASSISTANT EXAMINER: Shelborne, Kathryne E.  
LEGAL REPRESENTATIVE: Fay, Sharpe, Fagan, Minnich & McKee, LLP  
NUMBER OF CLAIMS: 24  
EXEMPLARY CLAIM: 1  
LINE COUNT: 1751

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB. The invention relates to a method of imparting anti-pathogenic properties to a substrate material comprising: (a) preparing a coating composition containing an anti-pathogenic agent consisting essentially of PVP-I and N-9 in a ratio of from about 100:0 to about 0:100 of PVP-I to N-9, the coating composition further containing a pre-mix solution with which the anti-pathogenic agent is intimately mixed in a ratio of from about 6:4 to about 8:2 of agent to pre-mix on a dry basis, and having a percent solids content of from about 5% to about 35% solids; (b) feeding the anti-pathogenic coating composition into a coating machine; (c) loading substrate onto the coating machine; (d) operating the coating machine such that the coating composition comes into intimate contact with at least one surface of the substrate; and (e) drying the coated substrate material. The invention further relates to the preparation of coating composition, the composition itself and to providing the coating in a dual or multilayered format,

10/772,890

wherein a first layer contains the active ingredient and a second layer contains the remaining coating components.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L21 ANSWER 11 OF 12 USPATFULL on STN

ACCESSION NUMBER: 1999:128156 USPATFULL Full-text  
TITLE: Anti-bacterial/anti-viral coatings, coating  
process and parameters thereof  
INVENTOR(S): Snyder, Jr., Donald E., Brockport, NY, United States  
PATENT ASSIGNEE(S): Viro-Kote, Inc., Dallas, TX, United States (U.S.  
corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5968538		19991019 <--
APPLICATION INFO.:	US 1997-904321		19970731 (8)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1996-603783, filed on 20 Feb 1996, now patented, Pat. No. US 5674513		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Dees, Jose' G.		
ASSISTANT EXAMINER:	Shelborne, Kathryn E.		
LEGAL REPRESENTATIVE:	Fay, Sharpe, Beall, Fagan, Minnich & McKee, LLP		
NUMBER OF CLAIMS:	17		
EXEMPLARY CLAIM:	1		
LINE COUNT:	1581		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to a method of imparting anti-pathogenic properties to a substrate material comprising: (a) preparing a coating composition containing an anti-pathogenic agent consisting essentially of PVP-I and N-9 in a ratio of from about 100:0 to about 0:100 of PVP-I to N-9, the coating composition further containing a pre-mix solution with which the anti-pathogenic agent is intimately mixed in a ratio of from about 6:4 to about 8:2 of agent to pre-mix on a dry basis, and having a percent solids content of from about 5% to about 35% solids; (b) feeding the anti-pathogenic coating composition into a coating machine; (c) loading substrate onto the coating machine; (d) operating the coating machine such that the coating composition comes into intimate contact with at least one surface of the substrate; and (e) drying the coated substrate material. The invention further relates to the preparation of coating composition, the composition itself and to providing the coating in a dual or multilayered format, wherein one or more layers contain anti-viral/anti-bacterial active ingredients.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L21 ANSWER 12 OF 12 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1987:583618 HCAPLUS Full-text  
DOCUMENT NUMBER: 107:183618  
TITLE: Sustained-release hydrogels containing amino acid  
functionalized units for ophthalmic or other use  
INVENTOR(S): Bawa, Rajan  
PATENT ASSIGNEE(S): Bausch and Lomb Inc., USA  
SOURCE: Eur. Pat. Appl., 34 pp.  
CODEN: EPXXDW  
DOCUMENT TYPE: Patent  
LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 219208	A2	19870422	EP 1986-306348	19860815 <--
EP 219208	A3	19880601		
EP 219208	B1	19920624		
R: BE, CH, DE, FR, GB, IT, LI, NL, SE				
US 4668506	A	19870526	US 1985-766741	19850816 <--
CA 1277236	C	19901204	CA 1986-515033	19860731 <--
JP 62103029	A	19870513	JP 1986-190686	19860815 <--
			US 1985-766741	A 19850816 <--

## PRIORITY APPLN. INFO.:

AB Sustained release hydrogels contain a drug in a polymer composed of acrylates which are hydrophilic, acrylates functionalized by an amino acid, and cross-linking agents. These hydrogels are especially useful as ophthalmic inserts or medicated contact lenses. Solution A is prepared from 2-hydroxyethyl methacrylate 85.3, isobornyl methacrylate 10, methacroyl glycine 6, and ethylene glycol dimethacrylate 0.5 g, and benzoin Me ether 0.5 g is added. Solution B is the same as solution A except pitocarpine HCl (I) 11.43 g is added. A triple layer contact lens is made by spincasting 9.8  $\mu$ L solution A; injecting 29.4  $\mu$ L solution B on the resulting polymer, spincasting, and injecting 9.8 mL solution A on the resulting 2-layer polymer. The resulting triple-spun contact lens has a polymer-drug layer encapsulated between 2 non-drug polymer layers. This composition released I into distilled water relatively rapidly for the first .apprx.20 h, and then released the drug at .apprx.0.4 mg/h until .apprx.170 h, when testing was stopped. Solution A was also polym. and the polymer was soaked in I to give another sustained-release composition, which had similar release characteristics to I-soaked Ocusert-20 after the first .apprx.15 h.



## SEARCH IN MEDLINE, BIOSIS, EMBASE, AND JAPIO

=&gt; d que stat l22

L4 37009 SEA FILE=HCAPLUS ABB=ON ?HYDROPHILIC?(P)?POLYMER?  
 L5 345 SEA FILE=HCAPLUS ABB=ON L4 AND (?VIRUS? OR ?VIRAL?)  
 L6 1 SEA FILE=REGISTRY ABB=ON (NITRILES OR ACRYLICS OR POLYVINYL  
 ALCOHOL OR SILASTIC RUBBER)/CN  
 L8 3 SEA FILE=REGISTRY ABB=ON "COPPER OXIDE"/CN  
 L9 1 SEA FILE=REGISTRY ABB=ON COPPER/CN  
 L10 83 SEA FILE=HCAPLUS ABB=ON L5 AND (L6 OR ?LATEX? OR ?NITRILE? OR  
 ?ACRYLIC? OR ?POLYVINYL?(W)?ALCOHOL? OR ?SILASTIC?(W)?RUBBER?)  
 L11 6 SEA FILE=HCAPLUS ABB=ON L10 AND (L8 OR L9 OR (?COPPER? OR  
 ?CUPRIC?) (W)?OXID? OR ?COPPER?)  
 L12 13 SEA FILE=HCAPLUS ABB=ON L10 AND (?ENCAPSULAT? OR (?FIRST? OR  
 ?SECOND?) (W)?LAYER)  
 L13 17 SEA FILE=HCAPLUS ABB=ON L11 OR L12  
 L14 10 SEA FILE=HCAPLUS ABB=ON L13 AND (PRD<20040204 OR PD<20040204)  
 L22 1 SEA L14

=&gt; d ibib abs l22 1-1.

L22 ANSWER 1 OF 1 EMBASE COPYRIGHT (c) 2007 Elsevier B.V. All rights  
 reserved on STN

ACCESSION NUMBER: 2000008300 EMBASE Full-text  
 TITLE: Highly loaded nanoparticulate carrier using an hydrophobic  
 antisense oligonucleotide complex.

AUTHOR: Berton M.; Allemann E.; Stein C.A.; Gurny R.

CORPORATE SOURCE: R. Gurny, School of Pharmacy, University of Geneva, Quai  
 E.-Ansermet, CH-1211 Geneva 4, Switzerland.  
 robert.gurny@pharm.unige.ch

SOURCE: European Journal of Pharmaceutical Sciences, (1999  
 ) Vol. 9, No. 2, pp. 163-170. .  
 Refs: 37

ISSN: 0928-0987 CODEN: EPSCED

PUBLISHER IDENT.: S 0928-0987(99)00049-4

COUNTRY: Netherlands

DOCUMENT TYPE: Journal; Article

FILE SEGMENT: 037 Drug Literature Index  
 039 Pharmacy

LANGUAGE: English

SUMMARY LANGUAGE: English

ENTRY DATE: Entered STN: 20 Jan 2000

Last Updated on STN: 20 Jan 2000

AB Antisense oligonucleotides, and particularly those with phosphorothioate  
 backbones, have emerged as potential gene specific therapeutic agents and are  
 currently undergoing evaluation in clinical trials for a variety of diseases.  
 In the area of HIV-1 therapeutics, targeting of oligonucleotides to infected  
 cells, such as macrophages, would be highly desirable. The present study was  
 designed to prepare and characterize oligonucleotide-loaded nanoparticles for  
 this purpose. Due to their hydrophilic characteristics, oligonucleotides are  
 difficult to entrap in polymeric particles. Here, the oligonucleotides were  
 first complexed with cetyltrimethylammonium bromide. The oligonucleotide-  
 loaded nanoparticles were prepared by the emulsification-diffusion method and  
 subsequently purified. In comparison with previous studies, a high  
 oligonucleotide-loading was achieved; 2.5, 5 and 10% oligonucleotide loading  
 were assessed. If the initial oligonucleotide content was 4%, this method  
 produced a final oligonucleotide loading of 1.9% with an entrapment efficiency

10/772,890

of 47%. The integrity of the oligonucleotide and of the polymer, in the final freeze-dried product, was retained. Copyright (C) 1999 Elsevier Science B.V.

## SEARCH HISTORY

=&gt; d his ful

(FILE 'HOME' ENTERED AT 18:21:36 ON 22 MAY 2007)

FILE 'HCAPLUS' ENTERED AT 18:21:52 ON 22 MAY 2007

E GABBAY JEFFREY/AU

- L1 31 SEA ABB=ON ("GABBAY J"/AU OR "GABBAY JACOB"/AU OR "GABBAY JEFFREY"/AU OR "GABBAY JEFFREY S S"/AU)
- L2 2 SEA ABB=ON L1 AND ?HYDROPHIL?(4A)?POLYMER?
- L3 ANALYZE L2 1-2 TI : 12 TERMS
- L4 37009 SEA ABB=ON ?HYDROPHILIC?(P)?POLYMER?
- L5 345 SEA ABB=ON L4 AND (?VIRUS? OR ?VIRAL?)

FILE 'REGISTRY' ENTERED AT 18:39:17 ON 22 MAY 2007

E NITRILE/CN

- L6 1 SEA ABB=ON (NITRILES OR ACRYLICS OR POLYVINYL ALCOHOL OR SILASTIC RUBBER)/CN
- E NITRILES/CN
- E ACRYLICS/CN
- L7 1 SEA ABB=ON ACRYLICS/CN
- E POLYVINYL ALCOHOL/CN
- E POLYVINYL ALCOHOLS/CN
- E SILASTIC RUBBER/CN
- E COPPER OXIDE/CN
- L8 3 SEA ABB=ON "COPPER OXIDE"/CN
- E COPPER/CN
- L9 1 SEA ABB=ON COPPER/CN

FILE 'HCAPLUS' ENTERED AT 18:43:40 ON 22 MAY 2007

- L10 83 SEA ABB=ON L5 AND (L6 OR ?LATEX? OR ?NITRILE? OR ?ACRYLIC? OR ?POLYVINYL?(W)?ALCOHOL? OR ?SILASTIC?(W)?RUBBER?)
- L11 6 SEA ABB=ON L10 AND (L8 OR L9 OR (?COPPER? OR ?CUPRIC?)(W)?OXID ? OR ?COPPER?)
- L12 13 SEA ABB=ON L10 AND (?ENCAPSULAT? OR (?FIRST? OR ?SECOND?)(W)?LAYER)
- L13 17 SEA ABB=ON L11 OR L12
- L14 10 SEA ABB=ON L13 AND (PRD<20040204 OR PD<20040204)

FILE 'USPATFULL' ENTERED AT 18:47:58 ON 22 MAY 2007

- L15 6686 SEA ABB=ON L13 AND (PRD<20040204 OR PD<20040204)
- L16 5833 SEA ABB=ON L15 AND ?ENCAPSULAT?
- L17 307 SEA ABB=ON L16 AND (?FIRST? OR ?SECOND?)(W)?LAYER?
- L18 114 SEA ABB=ON L17 AND ?MULTILAYER?
- L19 72 SEA ABB=ON L18 AND ?HYDROPHIL?(W)?POLYMER?
- L20 2 SEA ABB=ON L19 AND ?INACT?(3A)(?VIRUS? OR ?VIRAL?)

FILE 'HCAPLUS, USPATFULL' ENTERED AT 18:50:23 ON 22 MAY 2007

- L21 12 DUP REMOV L14 L20 (0 DUPLICATES REMOVED)

FILE 'MEDLINE, BIOSIS, EMBASE, JAPIO' ENTERED AT 18:50:36 ON 22 MAY 2007

- L22 1 SEA ABB=ON L14

FILE 'HCAPLUS, USPATFULL' ENTERED AT 18:52:11 ON 22 MAY 2007

SAV L17 HAN890L17/A \*\*This search was saved in case you would like

to see

additional citations.

FILE HOME

FILE HCAPLUS

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 22 May 2007 VOL 146 ISS 22  
FILE LAST UPDATED: 21 May 2007 (20070521/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

FILE REGISTRY

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 21 MAY 2007 HIGHEST RN 935505-97-8  
DICTIONARY FILE UPDATES: 21 MAY 2007 HIGHEST RN 935505-97-8

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

FILE USPATFULL

FILE COVERS 1971 TO PATENT PUBLICATION DATE: 22 May 2007 (20070522/PD)  
FILE LAST UPDATED: 22 May 2007 (20070522/ED)  
HIGHEST GRANTED PATENT NUMBER: US7222369  
HIGHEST APPLICATION PUBLICATION NUMBER: US2007113312  
CA INDEXING IS CURRENT THROUGH 22 May 2007 (20070522/UPCA)  
ISSUE CLASS FIELDS (/INCL) CURRENT THROUGH: 22 May 2007 (20070522/PD)  
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Dec 2006  
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Dec 2006

FILE MEDLINE

FILE LAST UPDATED: 22 May 2007 (20070522/UP). FILE COVERS 1950 TO DATE.

This file contains CAS Registry Numbers for easy and accurate substance identification.

10/772,890

FILE BIOSIS  
FILE COVERS 1969 TO DATE.  
CAS REGISTRY NUMBERS AND CHEMICAL NAMES (CNs) PRESENT  
FROM JANUARY 1969 TO DATE.

BIOSIS has been augmented with 1.8 million archival records from  
1926 to 1968. These records have been re-indexed to match current  
BIOSIS indexing.

RECORDS LAST ADDED: 16 May 2007 (20070516/ED)

FILE EMBASE  
FILE COVERS 1974 TO 22 May 2007 (20070522/ED)

EMBASE is now updated daily. SDI frequency remains weekly (default)  
and biweekly.

This file contains CAS Registry Numbers for easy and accurate  
substance identification.

FILE JAPIO  
FILE LAST UPDATED: 27 APR 2007 <20070427/UP>  
FILE COVERS APRIL 1973 TO JANUARY 25, 2007

>>> GRAPHIC IMAGES AVAILABLE <<<